Lantern Pharma Inc

LTRN10 Dec 2024
Healthcare
$4.17
+0.06 (+5.78%)
Lowest Today
$4.11
Highest Today
$4.84
Today’s Open
$4.17
Prev. Close
$3.98
52 Week High
$11.99
52 Week Low
$2.79
To Invest in Lantern Pharma Inc

Lantern Pharma Inc

Healthcare
LTRN10 Dec 2024
+0.06 (+5.78%)
1M
3M
6M
1Y
5Y
Low
$4.11
Day’s Range
High
$4.84
4.11
52 Week Low
$2.79
52-Week Range
52 Week High
$11.99
2.79
1 Day
-
1 Week
+14.54%
1 month return
-1.56%
3 month return
+8%
6 month return
-30.19%
1 Year return
-1.81%
3 Years return
-55.99%
5 Years return
-
10 Years return
-
Institutional Holdings
Vanguard Group Inc
3.37
Vanguard Total Stock Mkt Idx Inv
2.37
CM Management, LLC
1.72
Goss Wealth Management LLC
1.27
Vanguard Institutional Extnd Mkt Idx Tr
0.92
Geode Capital Management, LLC
0.81
Renaissance Technologies Corp
0.78

Market Status

Fundamentals
Market Cap
42.92 mln
PB Ratio
1.61
PE Ratio
0
Enterprise Value
15.16 mln
Total Assets
43.65 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Organisation
Lantern Pharma Inc
Employees
21
Industry
Biotechnology
CEO
Mr. Panna  Sharma PH.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities